Early lexicon development unifies content, accelerates understanding, and promotes rapid adoption of innovative new therapies within the rare disease community
Transitioning an orphan drug from clinical to early-stage commercial development comes with its own unique set of communication challenges. Professionals, patients, caregivers, and advocacy groups within orphan drug communities represent some of the most active information-seeking populations in healthcare. Managing the quality, content, and timing of premarket communications are important considerations for companies planning a launch within the rare disease space.
Participation in the development of a Global Brand Lexicon promotes collaboration
Team participation in the lexicon development process ensures that all stakeholders are able to input and feel a sense of ownership in the recommendations that will govern future brand-associated materials. While the Global Brand Lexicon provides the foundational language that will eventually evolve into product claims and promotional messaging—it can be utilized immediately in the development of early-stage commercialization assets, becoming your Global Team’s go-to resource for:
> Congress/Convention Materials
> Unbranded Promotion
> Internal Communications
> Product Labeling
> Clinical Articles
> Educational Materials
> Medical PR
> Investor Relations
We are thrilled to announce that Juice Pharma Worldwide are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.